Last reviewed · How we verify
Bupivacaine-Meloxicam
Bupivacaine-Meloxicam is a combination of a local anesthetic and a nonsteroidal anti-inflammatory drug designed to provide prolonged pain relief and reduce inflammation at the injection site.
Bupivacaine-Meloxicam is a combination of a local anesthetic and a nonsteroidal anti-inflammatory drug designed to provide prolonged pain relief and reduce inflammation at the injection site. Used for Local anesthesia and pain relief in surgical or procedural settings, Post-operative pain management.
At a glance
| Generic name | Bupivacaine-Meloxicam |
|---|---|
| Sponsor | TriHealth Inc. |
| Drug class | Local anesthetic + NSAID combination |
| Target | Voltage-gated sodium channels (bupivacaine); COX-1/COX-2 (meloxicam) |
| Modality | Small molecule |
| Therapeutic area | Pain Management / Anesthesia |
| Phase | Phase 3 |
Mechanism of action
Bupivacaine is a long-acting local anesthetic that blocks sodium channels in nerve fibers, preventing pain signal transmission. Meloxicam is an NSAID that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin-mediated inflammation. The combination aims to provide both immediate local anesthesia and sustained anti-inflammatory effects for pain management.
Approved indications
- Local anesthesia and pain relief in surgical or procedural settings
- Post-operative pain management
Common side effects
- Local injection site reactions
- Gastrointestinal effects (meloxicam component)
- Systemic toxicity from local anesthetic (rare)
Key clinical trials
- Phase 3 Herniorrhaphy Study for Postoperative Analgesia (EPOCH 2) (PHASE3)
- Total Knee Arthroplasty Infiltration Study for Postoperative Analgesia (PHASE2)
- Evaluation of the Efficacy and Safety of HTX-011 for Postoperative Analgesia Following Abdominoplasty Surgery (PHASE2)
- Phase 2B Upper Extremity Nerve Block Study (PHASE2)
- Bunionectomy Study for Postoperative Analgesia (EPOCH 1) (PHASE3)
- Phase 2 Bunionectomy HTX-011 Administration Study (PHASE2)
- Phase 2 Herniorrhaphy Study for Opioid Elimination (PHASE2)
- Pilot Herniorrhaphy Study for Postoperative Analgesia (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bupivacaine-Meloxicam CI brief — competitive landscape report
- Bupivacaine-Meloxicam updates RSS · CI watch RSS
- TriHealth Inc. portfolio CI